Anti VEGF strategies have been successful in the clinic for treatment of patients with several cancers, including colorectal cancer (CRC) (reviewed in [24]), in the form of Bevacizumab, a monoclonal antibody against VEGFA, and Aflibercept, a recombinant fusion protein blocking VEGFA and VEGFB signalling. This evidence concerns the gene VEGFA and colorectal cancer.